Cynvec is a privately owned, biotechnology company which applies the power of scientific innovation to discover and develop viral immunotherapeutic agents for the potential treatment of cancer.
Using the virus Sindbis, Cynvec is currently investigating the viral vector CYN102 as a possible treatment for ovarian cancer tumors.
“Nature gave us a gift in Sindbis. In mice, it has a natural ability to infect tumor cells almost exclusively, and naturally induces cell death in these tumor cells.” – Daniel Meruelo, Lead Scientist
To provide innovative and effective cancer solutions and establish a new standard of care in oncology using a novel science that employs the patient’s own immune system to improve clinical outcomes over a diverse range of cancers.